- VistaGen Therapeutics Inc (NASDAQ:VTGN) has announced topline results from its PALISADE-1 Phase 3 trial of PH94B for the acute treatment of social anxiety disorder.
- PH94B did not achieve its primary endpoint, as measured by change from baseline using the Subjective Units of Distress Scale (SUDS) compared to placebo.
- SUDS rating scale is used to measure the intensity of distress or nervousness in people with social anxiety.
- Social anxiety disorder affects an estimated 25 million Americans.
- Although the trial did not meet its primary endpoint, the tolerability profile of PH94B in PALISADE-1 was favorable and consistent with previously reported trials.
- No severe or serious adverse events were reported.
- The company will continue to develop PH94B’s potential as a new treatment option for multiple anxiety disorders, including acute treatment for social anxiety disorder in the ongoing PALISADE-2 Phase 3 trial and Phase 2 trial in adjustment disorder with anxiety.
- PALISADE-2 is on track for a topline readout in late 2022.
- Price Action: VTGN shares are down 81% at $0.20 during the premarket session on the last check Friday.
Apple Executives Spill The Beans: Here’s Why The iPhone Maker’s Chips Outshine Rivals
From just one product in 2010, Apple's chips now power everything from iPhones, iPads, Macs and even accessories like AirPods.
